Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a hidden nerve condition be more common in lung cancer than we think?

NCT ID NCT07075627

Knowledge-focused Sponsor: Addario Lung Cancer Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is looking at how often people with small cell lung cancer also have symptoms of Lambert-Eaton myasthenic syndrome (LEMS), a condition that affects the nerves and can cause muscle weakness. Researchers will review medical records and check for LEMS symptoms in adults diagnosed with small cell lung cancer. The goal is to better understand how common this condition is in this group of patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study succeeds, it could lead to better awareness and earlier detection of LEMS in people with small cell lung cancer, potentially improving their quality of life.
What could go wrong
This is an observational study, so it won't test any treatment. It may not capture all cases of LEMS, and the findings might not apply to everyone with small cell lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

United States

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult men or women meeting Age of Majority (AOM) at the time of consent 2. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF) 3. Any diagnosis of SCLC 4. Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required 5. Willing to comply with the requirements of the study Exclusion Criteria: 1. Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) \> 1 year prior to the SCLC diagnosis. 2. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lambert eaton myasthenic syndrome (LEMS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lambert-Eaton myasthenic syndrome small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lambert eaton myasthenic syndrome (LEMS) Small cell lung cancer ( SCLC )

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.